Article Text

PDF
THU0182 Dyslipoproteinemia and its relation with the activity of the disease and its treatment in a large spanish multicentric lupus cohort
  1. J. Pego-Reigosa1,
  2. I. Rúa2,
  3. C. Mouriño1,
  4. M. Galindo3,
  5. F. Lόpez-Longo4,
  6. J. Calvo5,
  7. M. García-Yébenes6,
  8. E. Tomero7,
  9. E. Uriarte8,
  10. C. Fito9,
  11. A. Sánchez10,
  12. A. Olivé11,
  13. M. Freire12,
  14. A. F-Nebro13
  15. on behalf of the RELESSER Group
  1. 1Rheumatology, H Meixoeiro, Vigo
  2. 2H Dr Negrín, Las Palmas
  3. 3H 12 octubre
  4. 4H Gregorio Marañόn, Madrid
  5. 5H Sierrallana, Cantabria
  6. 6SER Research Unit
  7. 7H La Princesa, Madrid
  8. 8H Donosti, Guipuzcoa
  9. 9CH Navarra, Navarra
  10. 10H Principe Asturias, Madrid
  11. 11H Germans Trias i Pujol, Barcelona
  12. 12CHUac, Coruña
  13. 13H Carlos Haya, Málaga, Spain

Abstract

Background Abnormalities in the lipid profile contribute to the increased risk of early atherosclerosis in patients with SLE

Objectives To study the dyslipoproteinemia in SLE and the influence of the disease activity and treatments on it.

Patients SLE patients from the RELESSER Registry with an active follow up in a Rheumatology Department.

Variables a) lipid profile: total, LDL/HDL cholesterol, triglycerides and atherogenic index (total/HDL cholesterol), b) SLE activity: SELENA-SLEDAI score, C3, C4 and anti-dsDNA antibodies and c) ongoing treatments. Dyslipoproteinemia is defined as the presence of at least one of the following criteria: total cholesterol ≥240mg/dl, triglycerides ≥180mg/dl or statins use.

Methods. Retrospective study of the data collected at the moment of the last evaluation of the patient. We calculate the prevalence of dyslipoproteinemia and the correlations between lipid profile and the SLE activity and treatments.

Results 583 patients were included (88.3% females, mean age: 45 years, SLE duration: median 111 months). Table 1 shows the results of the analysis of lipid profile.

The median of the SLEDAI score was 2 (IR: 0-4). 39.4% of the patients had a SLEDAI score =0. The SLE activity was mild (SLEDAI =1-4 points), moderate (5-9 points) and severe (≥10 points) in 43.4, 13.2 and 3.9% of the patients, respectively. Total cholesterol levels were significantly higher in the subgroup of patients with severe activity (p=0.009). The LDL cholesterol and the atherogenic index also were higher in that subgroup (p = n.s.). We did not find significant differences in the values of the lipid profile in the subgroup of patients with hypocomplementemia or positive anti-dsDNA antibodies.

The percentage of patients on statin therapy was significantly higher in the group of patients with severe lupus activity (p=0.05). The patients on current treatment with corticosteroids or with 2 immunosupressors had a higher prevalence of dyslipoproteinemia than those without corticosteroids or with ≤1 immunosupresor (p=0.009 and p=0.04, respectively). Patients on antimalarial therapy had lower triglycerides levels and lower prevalence of dysliproteinemia than those without that treatment (p close to 0.05).

Conclusions One third of the Spanish SLE patients had dyslipoproteinemia. Total cholesterol levels and statin requirement are significantly higher in the patients with higher disease activity. The use of corticosteroids and a more aggressive immunosupressive regimen are associated with higher prevalence of dyslipoproteinemia.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.